Gilead Sciences: Expanding Global HIV Treatment
Gilead Sciences recognizes the urgent need to expand access to antiretroviral therapy among populations where the HIV/AIDS epidemic is greatest, regardless of income or geography. The company has used its intellectual property rights to create innovative programs that have significantly increased the number of people receiving Gilead HIV medicines. As of the second quarter of 2012, 2.9 million patients in low- and middle-income countries received high-quality, low-cost versions of Gilead HIV medicines, representing one-third of all patients in these countries receiving therapy. As new medicines enter the advanced stages of development, Gilead begins planning ahead of product approval to ensure future access. Gilead’s goal is to change the traditional drug access paradigm in which new medicines are initially available only to wealthy populations and reduce the time required for medicines to be accessible to all patients.